RARE Daily

Allogene and Arbor Enter Gene Editing Licensing Deal for Allo CAR T Platform in Autoimmune Disease

March 12, 2024

Rare Daily Staff

Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease.

“The potential for CAR T as a therapeutic option for autoimmune disease has captured the collective imagination of the scientific community,” said Zachary Roberts, executive vice president of research and development and chief medical officer of Allogene. “Accordingly, this excitement created a new field for CAR T that has become quickly crowded, making differentiation key for future success. This agreement provides us access to Arbor’s proprietary gene-editing technology and know-how, allowing us to develop what we believe will be the most effective and broadly accessible CAR T approach for the treatment of autoimmune disease.”

Allogene designs next-generation allogeneic CAR T investigational products with a goal of reduced or chemotherapy-free conditioning that the company believes can sustain the scale of the autoimmune market while also meeting the unique requirements for these patients where they seek care. Allogene’s first autoimmune AlloCAR T investigational product is expected to enter phase 1 clinical trials in early 2025.

“Our strategy has long been to align ourselves with industry leaders who are working to harness the power of gene editing to change treatment paradigms and improve patient outcomes,” said Devyn Smith, CEO of Arbor. “We look forward to our collaboration with Allogene as they leverage our extensive gene-editing technologies to develop novel, differentiated allogeneic CAR T therapeutics for autoimmune diseases.”

Photo: Devyn Smith, CEO of Arbor


Stay Connected

Sign up for updates straight to your inbox.